$Affimed(AFMD)$ AFM13 + Keytruda in BV relapsed patients: the 46% CR rate fits nicely to an 88% best ORR with deepening responses to a 6 month progression free survival (pfs) rate of 77% at #ASH2018 now. From Dieter Hovekamp